U.S. markets open in 6 hours 21 minutes
  • S&P Futures

    3,638.75
    +6.00 (+0.17%)
     
  • Dow Futures

    30,032.00
    +34.00 (+0.11%)
     
  • Nasdaq Futures

    12,120.00
    +44.00 (+0.36%)
     
  • Russell 2000 Futures

    1,856.40
    +4.90 (+0.26%)
     
  • Crude Oil

    45.37
    +0.46 (+1.02%)
     
  • Gold

    1,807.70
    +3.10 (+0.17%)
     
  • Silver

    23.33
    +0.03 (+0.11%)
     
  • EUR/USD

    1.1918
    +0.0021 (+0.18%)
     
  • 10-Yr Bond

    0.8820
    0.0000 (0.00%)
     
  • Vix

    21.64
    -1.02 (-4.50%)
     
  • GBP/USD

    1.3384
    +0.0025 (+0.19%)
     
  • USD/JPY

    104.3980
    -0.0820 (-0.08%)
     
  • BTC-USD

    19,018.23
    +164.25 (+0.87%)
     
  • CMC Crypto 200

    376.64
    +6.89 (+1.86%)
     
  • FTSE 100

    6,432.17
    0.00 (0.00%)
     
  • Nikkei 225

    26,296.86
    +131.27 (+0.50%)
     

Sosei, AbbVie sign drug discovery deal worth up to $1 billion

·1 min read

(Reuters) - Japan's Sosei Group Corp will collaborate with AbbVie Inc on a drug discovery partnership that could be worth up to $1 billion.

Sosei shares soared 12.4% in Tokyo trading, compared with a 1.2% slide in the broader market.

The partnership will initially focus on the discovery of novel small molecules, targeting inflammatory and autoimmune diseases, the companies said in a news release on Thursday.

Sosei is eligible to receive up to $32 million in upfront and near-term milestone payments, along with future commercial milestones of up to $377 million, plus tiered royalties on sales.

The companies will work to discover and commercialise medicines that modulate G protein-coupled receptor (GPCR) targets.

Chicago-based AbbVie has the option to expand the collaboration to a total of four targets.

An expansion to four targets would put the total deal size "in a similar ballpark" to deals signed in 2019 with Genentech Inc and Takeda Pharmaceutical Co, a Sosei spokesman said.

The Genentech deal is worth up to $1 billion, while the Takeda partnership could total $1.2 billion.

(Reporting by Rocky Swift in Tokyo; editing by Anil D'Silva and Jason Neely)